Instalab
logoInstalab

Formiminoglutamic Acid (FIGlu)

Urine Test
Explore possible problems with folate use, with an exploratory urine marker that needs blood-test context.
4.9 (3,296 reviews)
Tested by Genova Diagnostics
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Self-collect at home
Kit shipped directly to you
Get results
Explained with clear next steps, no medical jargon

Should you take a Formiminoglutamic Acid (FIGlu) test?

This test is most useful if any of these apply to you.

Investigating an Unexplained Urine Result
Persistent elevation can support further evaluation, but it doesn't identify a cause on its own.
Taking Medicines That Affect Folate
This may add context when deficiency is suspected; its value for routine medication monitoring hasn't been established.
Eating Mostly Plants
B12 and, when needed, methylmalonic acid are the main tests for a possible B12 shortfall; this marker may add context.
Exploring Metabolic Health Research
Urinary FIGlu has been linked to arterial stiffness, without proven value for predicting heart attacks.

About Formiminoglutamic Acid (FIGlu)

Urinary FIGlu can rise when a folate-dependent step in protein breakdown is impaired. Folate deficiency is one explanation, but vitamin B12 deficiency, liver disease, and an inherited enzyme deficiency can produce the same finding. A high result alone doesn't identify which explanation applies.

FIGlu has a long history in the investigation of vitamin deficiencies and inherited metabolic disorders. Its use as a spot urine marker for early nutritional screening or preventive health remains exploratory. There are no widely accepted clinical decision thresholds for those purposes, and testing hasn't been shown to improve long-term health outcomes.

What the Number Reflects

Histidine is one of the building blocks of protein. Your liver breaks it down through several steps that produce urocanic acid, then other intermediate compounds, including FIGlu, before reaching glutamate.

Converting FIGlu to glutamate requires an enzyme and a usable form of folate. The enzyme transfers a small carbon-containing group from FIGlu to folate. When that reaction slows, more FIGlu can accumulate and leave your body in urine.

This test measures FIGlu in an unloaded spot urine sample, with the amount expressed relative to urine creatinine. Creatinine is a waste product formed largely in muscle. Adjusting for it reduces the effect of urine dilution, though differences in creatinine production and kidney function still matter.

Much of the older clinical research used a different procedure: a large oral dose of histidine followed by a timed urine collection. Some older assays also measured FIGlu together with urocanic acid. Those studies explain the biology, but their results and diagnostic performance can't be transferred directly to an unloaded spot sample.

Folate Deficiency and Anemia

Folate deficiency can interfere with the production of new blood cells and eventually cause megaloblastic anemia. Red blood cells are often oversized, and too few reach the circulation. Deficiency can also exist before anemia develops; it hasn't been established that spot urine FIGlu detects it earlier or more reliably than blood testing.

Historical histidine-loading studies found increased FIGlu in some people with folate deficiency, but the test missed others and could be abnormal for unrelated reasons. In one study, FIGlu alone identified 19 of 27 people with excessive combined excretion of FIGlu and urocanic acid. That was a comparison with another biochemical measurement, not a validated sensitivity estimate for diagnosing folate deficiency.

Vitamin B12 and the Folate Trap

Vitamin B12 helps recycle folate into forms that other reactions can use. Without enough B12, folate can accumulate in its methylated form while other usable forms become scarce. This is called the methylfolate trap. It helps explain why FIGlu can rise in B12 deficiency even when folate intake is adequate.

Older studies documented abnormal urinary histidine breakdown products in pernicious anemia and other B12-related disorders. Pernicious anemia develops when autoimmune damage to the stomach impairs B12 absorption. FIGlu cannot reliably distinguish this problem from folate deficiency, and an ordinary spot result hasn't been validated as a stand-alone measure of the folate trap.

Inherited Enzyme Deficiency

Persistently marked FIGlu excretion can occur in glutamate formiminotransferase deficiency. This condition results from disease-causing changes in both copies of the FTCD gene, usually one inherited from each parent. Affected people can have substantial urinary FIGlu despite adequate folate and B12.

Early reports described children with developmental problems and anemia, but many were investigated because they already had symptoms. A later study followed 18 children identified through newborn screening, with follow-up averaging about five years. Three needed individualized education plans for developmental delay; none had profound intellectual disability or profound anemia. Most were asymptomatic.

That small childhood study is reassuring, but it doesn't establish lifetime outcomes. The amount of FIGlu in urine alone doesn't predict how someone with FTCD deficiency will develop or whether treatment is needed. The urine measurement is a changing biochemical result; confirming the inherited cause requires a separate genetic evaluation.

Arteries and Metabolic Health

A study of 330 Korean adults measured FIGlu in fasting spot urine, adjusted for creatinine. Higher levels were associated with stiffer arteries, assessed by the speed of a pressure wave traveling between the arm and ankle. The association persisted after adjustment for several cardiovascular risk factors.

A separate analysis of 529 Korean adults found an association between urinary FIGlu and metabolic syndrome. Metabolic syndrome combines abnormalities in waist size, blood pressure, blood fats, and blood sugar. The FIGlu association was no longer independent after accounting for insulin resistance, so it didn't establish a separate metabolic risk signal.

Both studies examined people at one point in time. They didn't establish whether FIGlu predicts future heart attacks or diabetes, whether folate deficiency explained the associations, or whether lowering FIGlu would reduce risk.

Malnutrition, Liver Disease, and Other Causes

Severe malnutrition shows why FIGlu needs context. In one historical study, more than 80% of infants with protein malnutrition excreted excessive histidine breakdown products after a histidine load. These products included both FIGlu and urocanic acid. Some children had impaired breakdown at an earlier step, so FIGlu could remain low despite folate-related abnormalities.

Liver disease can also disturb this pathway. Historical studies found abnormal FIGlu excretion after histidine loading in people with liver disorders, but an isolated spot urine result cannot establish liver disease or its severity.

Small studies and case reports have described increased FIGlu in people already diagnosed with tumors, leukemia, or myeloma. These findings don't establish a role for FIGlu in cancer screening, and they don't make an isolated high result evidence of cancer.

What a Low Result Means

A low result doesn't establish that folate or B12 status is adequate. Less histidine entering the breakdown pathway can reduce FIGlu output. Rare inherited disorders affecting an earlier step, such as histidinemia, can also reduce its production.

When Results Can Be Misleading

  • Recent food intake: an older human study found lower urinary FIGlu during short-term fasting or calorie restriction. Histidine loading increases the amount entering the pathway, which is why loaded and unloaded results need separate interpretation.
  • Recent alcohol use: acute alcohol intoxication has been associated with increased urinary FIGlu. That finding alone doesn't establish nutritional folate deficiency.
  • Creatinine adjustment: differences in muscle mass, age, diet, and kidney function affect urine creatinine. Correcting for dilution doesn't remove every source of variation.
  • Medicines: drugs that affect folate metabolism can influence FIGlu. A result during treatment needs to be interpreted with the medication history and evidence of deficiency or toxicity.
  • Collection and analysis: a very dilute sample, improper storage, and differences between laboratory methods can affect comparability. Small changes between results may reflect collection or measurement variation.

Tracking Your Trend

Repeated measurements may show whether an unusual result persists, but there is no validated amount of change in spot urine FIGlu that proves improved folate status or better health. A falling value has to be interpreted alongside the cause of the original elevation, symptoms, and established blood markers.

What Moves This Biomarker

Evidence-backed interventions that affect your Formiminoglutamic Acid (FIGlu) level

↓ Decrease
Folic acid replacement for confirmed folate deficiency
Correcting folate deficiency can substantially reduce FIGlu excretion. Historical studies documented resolution of excessive excretion in some people with folate-responsive anemia. These studies generally used histidine loading or timed collections, so they don't establish the expected size of a change in an unloaded spot sample.
SupplementStrong Evidence
↓ Decrease
Vitamin B12 replacement for confirmed B12 deficiency
B12 replacement can reduce FIGlu-related urinary abnormalities when B12 deficiency impairs folate recycling. Historical clinical reports used histidine-loaded urine, and some assays measured FIGlu together with urocanic acid. They support the direction of the response but don't establish its size for an unloaded spot FIGlu result.
MedicationModerate Evidence
↑ Increase
Long-term treatment with anticonvulsants or phenothiazine antipsychotics
An older observational study found higher FIGlu excretion after histidine loading alongside lower serum and red cell folate during prolonged treatment. This pattern supports a real disturbance in folate status in the studied groups, although it doesn't establish the effect of every drug in these classes or the expected change in a spot sample.
MedicationModerate Evidence
↑ Increase
Methotrexate treatment without folinic acid rescue
Methotrexate interferes with folate-dependent reactions. In a small study of trophoblastic tumors, FIGlu excretion generally increased or remained high during regimens without folinic acid rescue. The study used histidine-loaded urine, and treatment groups differed, so it doesn't establish a uniform effect in current low-dose treatment.
MedicationModerate Evidence
↑ Increase
Chronic alcohol consumption
An older human study found increased urinary FIGlu during chronic alcohol administration. Alcohol-related changes in nutrition and folate metabolism can contribute, but a raised result doesn't prove a folate deficiency or identify the mechanism.
LifestyleModerate Evidence

Frequently Asked Questions

References

26 studies
  1. Ji-hee Haam, Young-sang Kim, Doo-yeoun Cho, Hyejin Chun, Sang-woon Choi, Yun Kyong Lee, Sang Wook Lim, Hyung Suk Koo, Moon Jong KimScientific Reports2021
  2. Ji-hee Haam, Yun Kyong Lee, Eunkyung Suh, Sang-woon Choi, Hyejin Chun, Young-sang KimClinical Chemistry and Laboratory Medicine (CCLM)2021
  3. Rebecca C. Ahrens-nicklas, Rebecca D. Ganetzky, Peggy W. Rush, Robert L. Conway, Can H. FiciciogluJournal of Inherited Metabolic Disease2019

Formiminoglutamic Acid (FIGlu) Testing Options

$405

See the chemical trail your metabolism leaves behind, and explore where your energy, gut, and nutrient pathways may be under strain.

Includes 49 biomarkers:
Formiminoglutamic Acid (FIGlu)3-Indoleacetic AcidPhenylacetic AcidDHPPA3-Hydroxyphenylacetic Acid
$509

A comprehensive at-home nutritional and metabolic assessment that analyzes key biomarkers to reveal functional nutrient needs and imbalances.

90 biomarkers
FSA/HSA eligible
No Rx needed
HIPAA compliant